Telix Pharmaceuticals Ltd — Share Issue/Capital Change 2024

Nov 27, 2024

Appendix 3G - Notification of issue, conversion or payment up of unquoted equity securities

==> picture [21 x 22] intentionally omitted <==

Announcement Summary

Entity name

TELIX PHARMACEUTICALS LIMITED

Date of this announcement

Thursday November 28, 2024

The +securities the subject of this notification are:

+Securities issued under an +employee incentive scheme that are subject to a restriction on transfer and are not being quoted on ASX until the restriction ends

Total number of +securities to be issued/transferred

		Total number of
ASX +security		+securities to be
code	Security description	issued/transferred	Issue date
TLXAP	SHARE RIGHTS	314,000	01/11/2024
TLXAO	SHARE APPRECIATION RIGHTS	4,133,200	25/11/2024
TLXAO	SHARE APPRECIATION RIGHTS	1,455,107	21/10/2024

Refer to next page for full details of the announcement

Appendix 3G - Notification of issue, conversion or payment up of unquoted equity securities

1 / 8

Appendix 3G - Notification of issue, conversion or payment up of unquoted equity securities

==> picture [21 x 22] intentionally omitted <==

Part 1 - Entity and announcement details

1.1 Name of entity

TELIX PHARMACEUTICALS LIMITED

We (the entity named above) give notice of the issue, conversion or payment up of the following unquoted +securities.

1.2 Registered number type Registration number ACN 616620369

1.3 ASX issuer code

TLX

1.4 The announcement is

New announcement

1.5 Date of this announcement

28/11/2024

Appendix 3G - Notification of issue, conversion or payment up of unquoted equity securities

2 / 8

Appendix 3G - Notification of issue, conversion or payment up of unquoted equity securities

==> picture [21 x 22] intentionally omitted <==

Part 2 - Issue details

2.1 The +securities the subject of this notification are:

+Securities issued under an +employee incentive scheme that are subject to a restriction on transfer and are not being quoted on ASX until the restriction ends

2.2a This notification is given in relation to an issue of +securities in a class which is not quoted on ASX and which:

has an existing ASX security code ("existing class")

Appendix 3G - Notification of issue, conversion or payment up of unquoted equity securities

3 / 8

Appendix 3G - Notification of issue, conversion or payment up of unquoted equity securities

==> picture [21 x 22] intentionally omitted <==

Part 3B - number and type of +securities the subject of this notification (existing class) where issue has not previously been notified to ASX in an Appendix 3B

Additional +securities in an existing class issued under an +employee incentive scheme ASX +security code and description

TLXAO : SHARE APPRECIATION RIGHTS

Date the +securities the subject of this notification were issued

25/11/2024

Will these +securities rank equally in all respects from their issue date with the existing issued +securities in that class Yes

Were any of the +securities issued to +key management personnel (KMP) or an +associate? Yes

Provide details of the KMP or +associates being issued +securities.

Provide details of the KMP	or +associates being issued +securities.
Name of KMP	Name of registered holder	Number of +securities
Darren Smith	Darren Smith	60,836
David Cade	David Cade	58,447
Darren Patti	Darren Patti	44,398

Please provide a URL link for a document lodged with ASX detailing the terms of the +employee incentive scheme or a summary of the terms

Refer to Telix Equity Incentive Plan Rules accessible at https://ir.telixpharma.com/governance/documents-charters and 2022 and 2023 Remuneration reports within the Telix 2022 and 2023 Annual Reports, respectively, accessible here https:/ /ir.telixpharma.com/reports

Any other information the entity wishes to provide about the +securities the subject of this notification

For administrative purposes, Telix is issuing additional Performance Share Appreciation Rights (PSARs) to eligible employees (other than the CEO) in accordance with its 2023 and 2024 long term incentive plan offer terms, to reflect the maximum 150% eligibility (at stretch target, subject to performance against the milestones and other conditions disclosed in Telix 2022 and 2023 Remuneration reports within Telix 2022 and 2023 Annual Reports, respectively, accessible here ht tps://ir.telixpharma.com/reports). Any PSAR grants that are not capable of vesting following testing at the appropriate times will lapse.

Issue details

Number of +securities

4,133,200

Additional +securities in an existing class issued under an +employee incentive scheme

Appendix 3G - Notification of issue, conversion or payment up of unquoted equity securities

4 / 8

Appendix 3G - Notification of issue, conversion or payment up of unquoted equity securities

==> picture [21 x 22] intentionally omitted <==

ASX +security code and description TLXAP : SHARE RIGHTS

Date the +securities the subject of this notification were issued

1/11/2024

Will these +securities rank equally in all respects from their issue date with the existing issued +securities in that class Yes

Were any of the +securities issued to +key management personnel (KMP) or an +associate? No

Please provide a URL link for a document lodged with ASX detailing the terms of the +employee incentive scheme or a summary of the terms

Refer to Telix Equity Incentive Plan Rules accessible at https://ir.telixpharma.com/governance/documents-charters

Any other information the entity wishes to provide about the +securities the subject of this notification

Retention rights granted to certain Telix employees: - Share rights in two tranches at zero exercise price, 100% maximum vesting subject to service conditions being met and individual performance - Total number granted: 314,000 share rights 157,000 zero-priced rights, restricted to 31 October 2027 (3 year retention period), and subject to testing/vesting on 1 November 2027; and 157,000 zero-priced rights, restricted to 31 October 2028 (4 year retention period), and subject to testing/vesting on 1 November 2028.

• Exercise period: all employees (excluding US): 2 years from the vesting date. For US employees: auto-exercise at the end of the restriction period (in November 2027 and November 2028, respectively)

Issue details

Number of +securities 314,000

Additional +securities in an existing class issued under an +employee incentive scheme

ASX +security code and description

TLXAO : SHARE APPRECIATION RIGHTS

Date the +securities the subject of this notification were issued

21/10/2024

Will these +securities rank equally in all respects from their issue date with the existing issued +securities in that class Yes

Were any of the +securities issued to +key management personnel (KMP) or an +associate? No

Appendix 3G - Notification of issue, conversion or payment up of unquoted equity securities

5 / 8

Appendix 3G - Notification of issue, conversion or payment up of unquoted equity securities

==> picture [21 x 22] intentionally omitted <==

Please provide a URL link for a document lodged with ASX detailing the terms of the +employee incentive scheme or a summary of the terms

Refer to Telix's Remuneration report, within its 2023 Annual Report accessible at https://ir.telixpharma.com/reports, and Telix Equity Incentive Plan Rules accessible at https://ir.telixpharma.com/governance/documents-charters Any other information the entity wishes to provide about the +securities the subject of this notification

Performance Share Appreciation Rights (PSARs) (exercise price: $18.45) granted to Telix employees under the Telix long term incentive plan. Vesting in March 2027 is subject to achievement of performance conditions and the terms of the Telix Equity Incentive Plan rules, with a measurement period of 2024-2026. Exercise period of 2 years from vesting.

Issue details Number of +securities 1,155,107

Additional +securities in an existing class issued under an +employee incentive scheme ASX +security code and description TLXAO : SHARE APPRECIATION RIGHTS Date the +securities the subject of this notification were issued 21/10/2024 Will these +securities rank equally in all respects from their issue date with the existing issued +securities in that class Yes Were any of the +securities issued to +key management personnel (KMP) or an +associate? No Please provide a URL link for a document lodged with ASX detailing the terms of the +employee incentive scheme or a summary of the terms Refer to Telix Equity Incentive Plan Rules accessible at https://ir.telixpharma.com/governance/documents-charters Any other information the entity wishes to provide about the +securities the subject of this notification Performance Share Appreciation Rights (PSARs) (exercise price: $18.45) granted to Telix employees under the Telix long term incentive plan. Vesting in March 2028 is subject to achievement of performance conditions and the terms of the Telix Equity Incentive Plan rules, with a measurement period of 1 January 2025 to 21 December 2027. Exercise period of 2 years from vesting.

Issue details

Number of +securities 300,000

Appendix 3G - Notification of issue, conversion or payment up of unquoted equity securities

6 / 8

Appendix 3G - Notification of issue, conversion or payment up of unquoted equity securities

==> picture [21 x 22] intentionally omitted <==

Part 4 - +Securities on issue

Following the issue, conversion or payment up of the +securities the subject of this notification, the +securities of the entity will comprise:

The figures in parts 4.1 and 4.2 below are automatically generated and may not reflect the entity's current issued capital if other Appendix 2A, Appendix 3G or Appendix 3H forms are currently with ASX for processing.

4.1 Quoted +securities (Total number of each +class of +securities issued and quoted on ASX)

	Total number of
ASX +security code and description	+securities on issue
TLX : ORDINARY FULLY PAID	334,683,357
4.2 Unquoted +securities (Total number of each +class of +securities issued but not quoted on ASX)
	Total number of
ASX +security code and description	+securities on issue
TLXAQ : SHARE RIGHTS EXPIRING 13-JUN-2027 EX NIL	80,000
TLXAR : PERFORMANCE RIGHTS	6,807,720
TLXAP : SHARE RIGHTS	1,743,000
TLXAO : SHARE APPRECIATION RIGHTS	16,097,220
TLXAT : CONVERTIBLE NOTES	3,250
TLXAM : OPTION EXPIRING 20-JUL-2026 EX $5.37	404,992
TLXAN : SHARE RIGHTS EXPIRING 20-JUL-2026 EX NIL	100,000
TLXAL : OPTION EXPIRING 27-JAN-2026 EX $4.38	349,361
TLXAS : PERFORMANCE SHARE INCENTIVE RIGHTS	440,000

4.2 Unquoted +securities (Total number of each +class of +securities issued but not quoted on ASX)

Appendix 3G - Notification of issue, conversion or payment up of unquoted equity securities

7 / 8

Appendix 3G - Notification of issue, conversion or payment up of unquoted equity securities

==> picture [21 x 22] intentionally omitted <==

Part 5 - Other Listing Rule requirements

5.1 Were the +securities issued under an exception in Listing Rule 7.2 and therefore the issue did not need any security holder approval under Listing Rule 7.1? Yes

5.1a Select the number of the applicable exception in Listing Rule 7.2

13

Appendix 3G - Notification of issue, conversion or payment up of unquoted equity securities

8 / 8